Table 1 P Valuesa for Association of TILs and TcellinfGEP with Clinical Outcomes

From: Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy

Biomarker

Chemotherapy

Pembrolizumab

BORb

PFSc

OSc

BORb

PFSc

OSc

TILsd

0.1664

0.1664

0.4887

0.0004

0.0002

0.0003

TcellinfGEPe

0.205

0.146

0.752

0.0003

8.51e-09

3.39e-07

  1. BOR best overall response, ECOG Eastern Cooperative Oncology Group, OS overall survival, PFS progression-free survival, TcellinfGEP T-cell‒inflamed gene expression profile, TIL tumor-infiltrating lymphocyte.
  2. aP values are 1-sided for pembrolizumab and 2-sided for chemotherapy.
  3. bLogistic regression model.
  4. cCox model.
  5. dTILs are square-root transformed; stratification variable, previous (neo)adjuvant therapy versus de novo metastatic disease at initial diagnosis, was used as a covariate in the model for evaluating the association of TILs with clinical outcomes.
  6. eThe baseline ECOG performance status was used as a covariate in the model for evaluating the association of TcellinfGEP with clinical outcomes.
Back to article page